



EAGLE
BIOSCIENCES

Human CD54 ELISA Kit

Catalog Number:

C5431-K01 (1 x 96 wells)

For Research Use Only. Not for use in diagnostic procedures.

v. 1.0

EAGLE BIOSCIENCES, INC.
20A Northwest Blvd., Suite 112, Nashua, NH 03063
Phone: 617-419-2019 Fax: 617-419-1110
WWW.EAGLEBIO.COM



1. Intended use

The Eagle Biosciences Human sICAM-1/CD54 ELISA Assay Kit is to be used for the in-vitro quantitative determination of soluble Inter Cellular Adhesion Molecule -1 (sICAM-1) in human serum, plasma, buffered solutions or cell culture medium. The assay will recognize both natural and recombinant human sICAM-1/CD54. The Eagle Biosciences Human sICAM-1/CD54 ELISA Assay kit is for Research Use Only.

2. Principle of the method

The Human sICAM-1/CD54 ELISA Assay Kit is a solid phase sandwich Enzyme Linked-Immuno-Sorbent Assay (ELISA). A monoclonal antibody specific for CD54 has been coated onto the wells of the microtiter strips provided. Samples, including standards of known CD54 concentrations and unknowns are pipetted into these wells. During the first incubation, the CD54 antigen and a biotinylated monoclonal antibody specific for CD54 are simultaneously incubated.

After washing, the enzyme (streptavidin-peroxydase) is added. After incubation and washing to remove all the unbound enzyme, a substrate solution is added to induce a coloured reaction product. The intensity of this coloured product is directly proportional to the concentration of CD54 present in the samples.

3. Reagents provided and reconstitution

Reagents (Store@2-8°C)	Quantity 1x96 well kit	Reconstitution
96 well microtitre strip plate	1	Ready to use (Pre-coated)
Plastic plate covers	2	n/a
Standard: 8ng/ml	2	Reconstitute as directed on the vial (see Assay preparation, section 8)
Control	2	Reconstitute as directed on the vial (see Assay preparation, section 8)
Standard Diluent (Buffer)	1 vial (25ml)	10x Concentrate, dilute in distilled water (see reagent preparation, section 8)
Biotinylated anti-CD54	1 vial (0.3ml)	Dilute in Biotinylated Antibody Diluent (see Assay preparation, section 8)
Biotinylated Antibody Diluent	1 vial (7ml)	Ready to use
Streptavidin-HRP	2 vials (5µl)	Add 0.5ml of HRP diluent prior to use (see Assay preparation, section 8)
HRP Diluent	1 vial (23ml)	Ready to use
Wash Buffer	1 vial (10ml)	200x Concentrate dilute in distilled water (see Assay preparation, section 8)
TMB Substrate	1 vial (11ml)	Ready to use
H ₂ SO ₄ stop reagent	1 vial (11ml)	Ready to use



4. Materials required but not provided

- Microtiter plate reader fitted with appropriate filters (450nm required with optional 630nm reference filter)
- Microplate washer or wash bottle
- 10, 50, 100, 200 and 1,000µl adjustable single channel micropipettes with disposable tips
- 50-300 µl multi-channel micropipette with disposable tips
- Multichannel micropipette reagent reservoirs
- Distilled water
- Vortex mixer
- Miscellaneous laboratory plastic and/or glass, if possible sterile

5. Storage Instructions

Store the Human CD54 ELISA Assay kit reagents between 2 and 8°C. Immediately after use remaining reagents should be returned to cold storage (2-8°C). Expiry of the Human sICAM-1/CD54 ELISA Assay Kit and reagents is stated on box front labels. The expiry of the kit components can only be guaranteed if the components are stored properly, and if, in case of repeated use of one component, the reagent is not contaminated by the first handling.

- **Wash Buffer:** Once prepared store at 2-8°C for up to 1 week
- **Standard Diluent Buffer:** Once prepared store at 2-8°C for up to 1 week
- **Standards / Controls:** Once prepared use immediately and do not store
- **Biotinylated Secondary Antibody:** Once prepared use immediately and do not store
- **Streptavidin-HRP:** Once prepared use immediately and do not store

6. Specimen collection, processing & storage

Cell culture supernatants, serum, plasma or other biological samples will be suitable for use in the assay. Remove serum from the clot or red cells, respectively, as soon as possible after clotting and separation.

Cell culture supernatants:

Remove particulates and aggregates by spinning at approximately 1000 x g for 10 min.

Serum:

Avoid any unintentional stimulation of the cells by the procedure. Use pyrogen/endotoxin free collecting tubes. Serum should be removed rapidly and carefully from the red cells after clotting. For that, after clotting, centrifuge at approximately 1000 x g for 10 min and remove serum.

Plasma:

EDTA, citrate and heparin plasma can be assayed. Spin samples at 1000 x g for 30 min to remove particulates. Harvest plasma.

**Storage:**

If not analyzed shortly after collection, samples should be aliquoted (250-500µl) to avoid repeated freeze-thaw cycles and stored frozen at -70°C . Avoid multiple freeze-thaw cycles of frozen specimens.

Recommendation: Do not thaw by heating at 37°C or 56°C . Thaw at room temperature and make sure that sample is completely thawed and homogeneous before use. When possible avoid use of badly haemolysed or lipemic sera. If large amounts of particles are present these should be removed prior to use by centrifugation or filtration.

7. Safety & precautions for use

- Handling of reagents, serum or plasma specimens should be in accordance with local safety procedures, e.g. CDC/NIH Health manual: "Biosafety in Microbiological and Biomedical Laboratories" 1984
- The human serum included in this kit has been tested and found non reactive for HbsAg, anti HIV1 & 2 and anti VHC. Nevertheless, no known method can offer complete assurance that human blood derivatives will not transmit hepatitis, AIDS or other infections. Therefore handling of reagents, serum or plasma specimens should be in accordance with local safety procedures
- Laboratory gloves should be worn at all times
- Avoid any skin contact with H_2SO_4 and TMB. In case of contact, wash thoroughly with water
- Do not eat, drink, smoke or apply cosmetics where kit reagents are used
- Do not pipette by mouth
- When not in use, CD54 ELISA Assay kit components should be stored refrigerated or frozen as indicated on vials or bottles labels
- All reagents should be warmed to room temperature before use. Lyophilized standards should be discarded after use
- Once the desired number of strips has been removed, immediately reseal the bag to protect the remaining strips from deterioration
- Cover or cap all reagents when not in use
- Do not mix or interchange reagents between different lots
- Do not use reagents beyond the expiration date of the kit
- Use a clean disposable plastic pipette tip for each reagent, standard, or specimen addition in order to avoid cross contamination, for the dispensing of H_2SO_4 and substrate solution, avoid pipettes with metal parts
- Use a clean plastic container to prepare the washing solution
- Thoroughly mix the reagents and samples before use by agitation or swirling
- All residual washing liquid must be drained from the wells by efficient aspiration or by decantation followed by tapping the plate forcefully on absorbent paper. Never insert absorbent paper directly into the wells
- The TMB solution is light sensitive. Avoid prolonged exposure to light. Also, avoid contact of the TMB solution with metal to prevent colour development. Warning TMB is toxic avoid direct contact with hands. Dispose off properly
- If a dark blue colour develops within a few minutes after preparation, this indicates that the TMB solution has been contaminated and must be discarded. Read absorbance's within 1 hour after completion of the assay



- When pipetting reagents, maintain a consistent order of addition from well-to-well. This will ensure equal incubation times for all wells
- Follow incubation times described in the assay procedure
- Dispense the TMB solution within 15 min of the washing of the microtitre plate

8. Assay Preparation

Bring all reagents to room temperature before use

8.1. Assay Design

Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running zeros and standards. Each sample, standard and zero should be tested **in duplicate**. Remove sufficient Microwell Strips for testing from the pouch immediately prior to use. Return any wells not required for this assay with desiccant to the pouch. Seal tightly and return to 2-8°C storage.

Example plate layout (example shown for a 6 point standard curve)

	Standards		Sample Wells									
	1	2	3	4	5	6	7	8	9	10	11	12
A	8	8										
B	4	4										
C	2	2										
D	1	1										
E	0.5	0.5										
F	0.25	0.25										
G	Control	Control										
H	zero	zero										

All remaining empty wells can be used to test samples in duplicate

8.2. Preparation of Wash Buffer

Dilute the (200x) wash buffer concentrate 200 fold with distilled water to give a 1x working solution. Pour entire contents (10 ml) of the Washing Buffer Concentrate into a clean 2,000 ml graduated cylinder. Bring final volume to 2,000 ml with glass-distilled or deionized water. Mix gently to avoid foaming. Transfer to a clean wash bottle and store at 2°-8°C for up to 1 week.

8.3. Preparation of Standard Diluent Buffer

Add the contents of the vial (10x concentrate) to 225ml of distilled water before use. This solution can be stored at 2-8°C for up to 1 week.



8.4. Preparation of Standard

Standard vials must be reconstituted with the volume of standard diluent shown on the vial immediately prior to use. This reconstitution gives a stock solution of 8ng/ml of CD54. **Mix the reconstituted standard gently by inversion only.** Serial dilutions of the standard are made directly in the assay plate to provide the concentration range from 8 to 0.25ng/ml. A fresh standard curve should be produced for each new assay.

- Immediately after reconstitution add 200µl of the reconstituted standard to wells A1 and A2, which provides the highest concentration standard at 8ng/ml
- Add 100µl of Standard Diluent to the remaining standard wells B1 and B2 to F1 and F2
- Transfer 100µl from wells A1 and A2 to B1 and B2. Mix the well contents by repeated aspirations and ejections taking care not to scratch the inner surface of the wells
- Continue this 1:1 dilution using 100µl from wells B1 and B2 through to wells F1 and F2 providing a serial diluted standard curve ranging from 8 to 0.25ng/ml
- Discard 100µl from the final wells of the standard curve (F1 and F2)

Alternatively these dilutions can be performed in separate clean tubes and immediately transferred directly into the relevant wells.

8.5. Preparation of Control

Control has to be reconstituted with the volume of standard buffer diluent indicated on the vial. Reconstitution of the freeze-dried material with the indicated volume, will give a solution for which the CD54 concentration is stated on the vial. Do not store after use.

8.6. Preparation of Samples

Before testing, serum or plasmas samples have to be diluted 1:100 or 1:200 in standard diluent (buffer).

8.7. Preparation of Biotinylated anti-CD54

It is recommended this reagent is prepared immediately before use. Dilute the biotinylated anti-CD54 with the biotinylated antibody diluent in an appropriate clean glass vial using volumes appropriate to the number of required wells. Please see example volumes below:

Number of wells required	Biotinylated Antibody (µl)	Biotinylated Antibody Diluent (µl)
16	40	1060
24	60	1590
32	80	2120
48	120	3180
96	240	6360



8.8. Preparation of Streptavidin-HRP

It is recommended to centrifuge vial for a few seconds in a microcentrifuge to collect all the volume at the bottom. Dilute the 500 μ l vial with 0.5ml of HRP diluent **immediately before use**. Do-not keep this diluted vial for future experiments. Further dilute the HRP solution to volumes appropriate for the number of required wells in a clean glass vial. Please see example volumes below:

Number of wells required	Streptavidin-HRP (μ l)	Streptavidin-HRP Diluent (ml)
16	30	2
24	45	3
32	60	4
48	75	5
96	150	10

9. Method

We strongly recommend that every vial is mixed thoroughly without foaming prior to use except the standard vial which must be mixed gently by inversion only.

Prepare all reagents as shown in section 8.

Note: Final preparation of Biotinylated anti-CD54 (section 8.7) and Streptavidin-HRP (section 8.8) should occur immediately before use.

Assay Step	Details
1. Addition	Prepare Standard curve as shown in section 8.4
2. Addition	Add 100 μ l of each standard, sample, control and zero (standard diluent) in duplicate to appropriate number of wells
3. Addition	Add 50 μ l of diluted biotinylated anti-CD54 to all wells
4. Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for 1 hours
5. Wash	Remove the cover and wash the plate as follows: a) Aspirate the liquid from each well b) Dispense 0.3 ml of 1x washing solution into each well c) Aspirate the contents of each well d) Repeat step b and c another two times
6. Addition	Add 100 μ l of Streptavidin-HRP solution into all wells
7. Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for 30 min
8. Wash	Repeat wash step 5.



9.	Addition	Add 100µl of ready-to-use TMB Substrate Solution into all wells
10.	Incubation	Incubate in the dark for 10-20 minutes* at room temperature. Avoid direct exposure to light by wrapping the plate in aluminium foil
11.	Addition	Add 100µl of H₂SO₄:Stop Reagent into all wells
Read the absorbance value of each well (immediately after step 11.) on a spectrophotometer using 450 nm as the primary wavelength and optionally 630 nm as the reference wave length (610 nm to 650 nm is acceptable).		

**Incubation time of the substrate solution is usually determined by the ELISA reader performance. Many ELISA readers only record absorbance up to 2.0 O.D. Therefore the colour development within individual microwells must be observed by the analyst, and the substrate reaction stopped before positive wells are no longer within recordable range*

10. Data Analysis


Calculate the average absorbance values for each set of duplicate standards and samples. Ideally duplicates should be within 20% of the mean.

Generate a linear standard curve by plotting the average absorbance of each standard on the vertical axis versus the corresponding human CD54 standard concentration on the horizontal axis.

The amount of CD54 in each sample is determined by extrapolating OD values against CD54 standard concentrations using the standard curve.

Example of CD54 standard curve

Standard	CD54 Conc ng/ml	OD (450nm) Mean	CV (%)
1	8	2.343	4.0
2	4	1.457	4.7
3	2	0.761	6.5
4	1	0.527	3.5
5	0.5	0.360	5.7
6	0.25	0.253	9.2
Zero	0	0.136	-



Note: curve shown above should not be used to determine results. Every laboratory must produce a standard curve for each set of microwell strips assayed.

For sample serum or plasmas which have been diluted 1:100 according to the protocol, the calculated concentration should be multiplied by the dilution factor (x100)



11. Assay limitations

Do not extrapolate the standard curve beyond the maximum standard curve point. The dose-response is non-linear in this region and good accuracy is difficult to obtain. Concentrated samples above the maximum standard concentration must be diluted with Standard diluent or with your own sample buffer to produce an OD value within the range of the standard curve. Following analysis of such samples always multiply results by the appropriate dilution factor to produce actual final concentration.

The influence of various drugs on end results has not been investigated. Bacterial or fungal contamination and laboratory cross-contamination may also cause irregular results.

Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Completely empty wells before dispensing fresh Washing Buffer, fill with Washing Buffer as indicated for each wash cycle and do not allow wells to sit uncovered or dry for extended periods.

Disposable pipette tips, flasks or glassware are preferred, reusable glassware must be washed and thoroughly rinsed of all detergents before use.

As with most biological assays conditions may vary from assay to assay therefore **a fresh standard curve must be prepared and run for every assay.**

12. Performance Characteristics

12.1. Sensitivity

The sensitivity, minimum detectable dose of human CD54 using this Eagle Biosciences CD54 ELISA kit was found to be **<0.1ng/ml**. This was determined by adding 3 standard deviations to the mean OD obtained when the zero standard was assayed 32 times.

12.2. Precision

Intra-Assay					Inter-Assay				
Sample	n	Mean (ng/mL)	SD	CV%	Sample	n	Mean (ng/mL)	SD	CV %
A	8	7.82	0.081	1.03	A	22	8.05	0.317	3.93
B	8	1.17	0.033	2.82	B	22	1.03	0.084	8.15

12.3. Normal Serum Values

The average concentration of sICAM-1/CD54 detected in 77 normal human serum is 571+/-168 ng/ml ranging from 219 to 1042 ng/ml.



13. References

- Atteritano, M. et al., Effects of the phytoestrogen genistein on some predictors of cardiovascular risk in osteopenic, postmenopausal women: a 2-years randomized, double-blind, placebo-controlled study. *J Clin Endocrinol Metab.*,2007;92: 3068 -3075
- Bajo, M. A. et al., *Nephrol. Dial. Transplant.* Low-GDP peritoneal dialysis fluid ('balance') has less impact in vitro and ex vivo on epithelial-to-mesenchymal transition (EMT) of mesothelial cells than a standard fluid. *Transplant.*,2011; 26(1): 282-291
- Bechara D. et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. *J. Immunol.*, 2001; 167(6): 3099 – 3106
- Castilla, P. et al. Concentrated red grape juice exerts antioxidant, hypolipidemic, and antiinflammatory effects in both hemodialysis patients and healthy subjects. *Am J Clin Nutr.*,2006;84(1): 252-62
- Castilla, P. et al. Comparative effects of dietary supplementation with red grape juice and vitamin E on production of superoxide by circulating neutrophil NADPH oxidase in hemodialysis patients. *Am. J. Clinical Nutrition*,2008; 87(4): 1053-1061
- Chen, M. C. et al. Percutaneous transluminal mitral valvuloplasty reduces circulating vascular cell adhesion molecule-1 in rheumatic mitral stenosis. *Chest*,2004; 125(4): 1213-7
- Cosentino, F. et al. Impact of Fasting Glycemia and Regional Cerebral Perfusion in Diabetic Subjects: A Study With Technetium-99m-Ethyl Cysteinate Dimer Single Photon Emission Computed Tomography. *Stroke*,2009; 40(1): 306-308
- Diamanti-Kandarakis, E. et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of Metformin. *Hum Reprod.*, 2006; 21(6): 1426-31
- Galea, P. et al. Circulating cell adhesion molecules in HIV1-infected patients as indicator markers for AIDS Progression. *Res Immunol.*, 1997; 148(2): 109-17
- Grooteman, M. P. et al. Patient characteristics rather than the type of dialyser predict the variability of endothelial derived surface molecules in chronic haemodialysis patients. *Nephrol Dial Transplant.*,2005; 20(12): 2751-8.
- Hartweg, J. et al. Stability of Soluble Adhesion Molecules, Selectins, and C-Reactive Protein at Various Temperatures: Implications for Epidemiological and Large-Scale Clinical Studies. *Clin. Chem.*,2007; 53(10): 1858-1860
- Herder, C. et al. Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. *Diabetes*,2006; 55(8): 2340-6



Koenig, W. et al. CD14 C(-260)-->T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease. *J Am Coll Cardiol.*, 2002; 40(1): 34-42.

Llorente, L. et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. *Arthritis Rheum.*,2000; 43(8): 1790-800

Lund, S.S. Et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. *Eur. J. Endocrinol.*,2008;158(5): 631-641

Manneras-Holm, L. et al. Coagulation and Fibrinolytic Disturbances in Women with Polycystic Ovary Syndrome. *J. Clin. Endocrinol. Metab.*,2011; 96(4): 1068-1076

Monchanin, G. et al. Effects of progressive and maximal exercise on plasma levels of adhesion molecules in athletes with sickle cell trait with or without alpha-thalassemia. *J Appl Physiol.*,2007; 102(1): 169-73

Persson, F. et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. *Diabetes*,2006; 55(12): 3550-5

Persson, F. et al. Renal Effects of Aliskiren Compared With and in Combination With Irbesartan in Patients With Type 2 Diabetes, Hypertension, and Albuminuria. *Diabetes Care*,2009; 32(10): 1873-1879

Pritchard J. et al. A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barre syndrome. *Neurology*, 2003; 61(9): 1282 – 1284

Rothenbacher D. et al. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. *Eur. Heart J.*, 2005; 26(16): 1640 – 1646

Rothenbacher, D. et al. Physical activity, coronary heart disease, and inflammatory response. *Arch Intern Med.*,2003;163(10): 1200-5

Sammons J. et al. Mechanisms mediating the inhibitory effect of all-trans retinoic acid on primitive hematopoietic stem cells in human long-term bone marrow culture. *Stem Cells* 2000; 18(3): 214 – 219

Sithu, S. D. et al. Membrane-type 1-Matrix Metalloproteinase Regulates Intracellular Adhesion Molecule-1 (ICAM-1)-mediated Monocyte Transmigration. *J. Biol. Chem.*,2007; 282(34): 25010-25019

Sookoian, S. et al. Should Nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome? A Cross-Sectional Comparison With Adult Treatment Panel III Criteria in Nonobese Nondiabetic Subjects: Response to Musso et al. *Diabetes Care*,2008; 31(5): e42-.

Stam, F. et al. Impaired renal function is associated with markers of endothelial dysfunction and increased inflammatory activity. *Nephrol Dial Transplant*,2003; 18(5): 892-8



Thorand, B. et al. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. *Arterioscler Thromb Vasc Biol.*,2006; 26(2): 398-405

Tsakadze, N. L. et al. Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). *J Biol Chem.*,2006; 281(6): 3157-64

Van Dam, B. et al. Vitamin E inhibits lipid peroxidation-induced adhesion molecule expression in endothelial cells and decreases soluble cell adhesion molecules in healthy subjects. *Cardiovasc Res.*,2003; 57(2): 563-571

van Ree, R. M. et al. Abdominal obesity and smoking are important determinants of C-reactive protein in renal transplant recipients. *Nephrol Dial Transplant*,2005; 20(11): 2524-31

Wang, X. M. et al. Effects of perindopril on soluble intercellular adhesion molecule-1 in patients with congestive heart failure. *Heart*,2002; 88(4): 417



14. Assay Summary

Total procedure length : 1h45mn

Add 100µl sample and diluted standard and 50µl Biotinylated anti-CD54



Incubate 1 hours at room temperature



Wash three times



Add 100µl of Streptavidin-HRP



Incubate 30min at room temperature



Wash three times



Add 100 µl of ready-to-use TMB
Protect from light. Let the color develop for 10-20 mn.



Add 100 H₂SO₄



Read Absorbance at 450 nm



Warranty Information

Eagle Biosciences, Inc. warrants its Product(s) to operate or perform substantially in conformance with its specifications, as set forth in the accompanying package insert. This warranty is expressly limited to the refund of the price of any defective Product or the replacement of any defective Product with new Product. This warranty applies only when the Buyer gives written notice to the Eagle Biosciences within the expiration period of the Product(s) by the Buyer. In addition, Eagle Biosciences has no obligation to replace Product(s) as result of a) Buyer negligence, fault, or misuse, b) improper use, c) improper storage and handling, d) intentional damage, or e) event of force majeure, acts of God, or accident.

Eagle Biosciences makes no warranties, either expressed or implied, except as provided herein, including without limitation thereof, warranties as to marketability, merchantability, fitness for a particular purpose or use, or non-infringement of any intellectual property rights. In no event shall the company be liable for any indirect, incidental, or consequential damages of any nature, or losses or expenses resulting from any defective product or the use of any product. Product(s) may not be resold, modified, or altered for resale without prior written approval from Eagle Biosciences, Inc.

For further information about this kit, its application or the procedures in this kit, please contact the Technical Service Team at Eagle Biosciences, Inc. at info@eaglebio.com or at 866-411-8023.